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Etiology of Cancer Associated 
Thromboembolism (CAT), and 
Diet, Lifestyle and Medicine 
to Reduce Cancer and Venous 
Thromboembolism
Kenji Yokoyama
Abstract
Cancer is one of the leading causes of death in developed countries, and cancer 
patients often develop venous thromboembolism (VTE). VTE is the second leading 
cause of death in cancer patients receiving chemotherapy. The incidence of VTE 
varies among cancers, and it is highest in pancreatic cancer patients. Increased 
white blood cells and thrombocytosis are risk factors for developing cancer-
associated VTE. Some other proteins (tissue factor, podoplanin, P-selectin, and 
plasminogen activator inhibitor-1) may also play roles in thrombus formation in 
cancer patients. Certain diets and nutrition (e.g., enough fish, vegetables, and 
fruits) may reduce the risk of VTE. Certain diets and nutrition also may reduce the 
risk of cancer, and alcohol drinking and cigarette smoking definitely increase risk 
of cancer. Some studies suggest that aspirin, a widely used antiplatelet drug, may 
reduce cancer incidence and mortality, but other studies fail to show the beneficial 
effects of aspirin.
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1. Introduction
Cancer is one of the leading causes of death in developed countries including 
Japan. According to the Japanese Cancer Institute registry data, 1,017,200 patients 
were estimated to be newly diagnosed with cancer, and 380,300 patients were 
estimated to die from cancer in 2019 [1]. Colon cancer is the most often diagnosed 
in Japanese people, followed by gastric and lung cancer. Lung cancer most often 
causes death related to cancer, followed by colon and gastric cancer. Approximately 
half of Japanese people suffer from cancer during their lifetime, and one-third die 
from cancer. Venous thromboembolism (VTE) is a common and serious complica-
tion in patients with cancer. The risk of VTE in cancer patients is severalfold higher 
than that in individuals without cancer [2, 3], and VTE is the second leading cause 
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of death in cancer patients undergoing chemotherapy after death directly related to 
cancer [4]. Therefore, it is important to prevent and treat cancer-associated VTE to 
improve prognosis of cancer.
2. History of cancer-associated thrombosis
French physician Armand Trousseau first described the relationship  
between cancer and thrombosis when he reported multiple cancer patients 
complicated with “phlegmasia alba dolens” caused by deep vein thrombosis in 
1865 [5]. He speculated that excess of fibrin and hypercoagulable state of blood 
caused thrombosis in these patients. Two years later, he suffered from “phleg-
masia alba dolens,” and he died from gastric cancer. Since then, many studies 
have revealed the relationships between cancer and thrombosis. Presently, it 
is well known that thrombosis, i.e., venous thromboembolism (VTE), arterial 
thrombosis, disseminated intravascular coagulation, and thrombotic microan-
giopathy, often occurs in cancer patients, and thrombosis occurring in cancer 
patients become to be recognized as cancer-associated thrombosis (CAT) 
(Table 1).
3. Epidemiology and etiology of venous thromboembolism
Among CAT, VTE most often occurs in cancer patients. VTE is a disease 
that includes deep vein thrombosis (DVT), which usually occurs in the lower 
legs, and pulmonary embolisms (PE). Most isolated distal DVTs do not extend 
to the proximal veins and remain uneventful, whereas parts of clot may break 
off from proximal DVTs and they may cause potentially life-threatening 
PE. VTE is the third frequent cardiovascular diseases in Western countries 
next to myocardial infarction and stroke, and it is estimated that annual inci-
dence of VTE is 1–2 per 1000 adults in the USA [6]. Racial differences may  
exist in the incidence of VTE, and it is reported that the incidence of VTE in 
whites is five times higher than that in Asians [7]. Previously, the incidence of 
VTE in Japanese population was supposed to be low, but more Japanese patients 
have been diagnosed with VTE, recently. The number of patients diagnosed 
with PE was 28 per 1,000,000 people in 1996, and it increased to 126 in  
2011 [8].
There are several risk factors that induce VTE, and cancer is one of the main risk 
factors for VTE (Table 2). It has been reported that cancer is associated with 18% 
of all VTE, and the overall risk of VTE was increased sevenfold in patients with a 
malignancy (odds ratio [OR], 6.7; 95% confidence interval [CI], 5.2–8.6) vs. persons 
without malignancy [9].
Table 1. 
Cancer-associated thrombosis.
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4. Risk factors for cancer-associated venous thromboembolism
Incidence rates of VTE increase with age in the general population. Likewise, 
cancer-associated VTE occurs more often in the elderly population than younger 
population. Khorana et al. reported that age 65 or older is an independent risk fac-
tor for developing cancer-associated VTE. Cancer-associated VTE is more common 
in female sex and black race [3]. Obesity; complications such as respiratory disease, 
kidney disease, and infection; and poor performance status are also risk factors for 
cancer-associated VTE [10–12].
The risk of VTE varies by cancer site, and meta-analysis of several studies proves 
that the incidence of VTE is highest in the pancreatic cancer patients, followed by 
hematological malignancy and brain tumor patients [13]. VTE more often occurs in 
patients with advanced cancer than in patients with early cancer [14]. The incidence 
of VTE also varies by cancer histology, is higher in lung adenocarcinoma patients 
than in lung squamous cell carcinoma patients [15], and is higher in high-grade 
lymphoma patients than in low-grade lymphoma patients [16, 17].
Cancer treatment also affects VTE incidence. VTE is a common  complication 
of surgery, regardless of whether it is cancer surgery or not, and adequate prophy-
laxis is recommended in guidelines including Japanese guideline [18]. However, 
among cancer patients who received adequate VTE prophylaxis after surgery, 
2.1% of them developed massive VTE and 0.8% of them died [19]. Many types of 
anticancer drugs, such as cisplatin, l-asparaginase, and bevacizumab, also increase 
risk of thrombosis in cancer patients. Especially, the incidence of VTE is very high 
in multiple myeloma patients receiving immunomodulatory drugs (e.g., thalido-
mide, lenalidomide, and pomalidomide), and these patients need primary preven-
tion of VTE by using antithrombotic drugs. Cancer patients often need indwelling 
central venous catheter (CVC) for delivery of intravenous drugs, parenteral 
nutrition, and collecting blood samples. Indwelling CVC increases risk of develop-
ing VTE, and it is estimated that the risk of symptomatic catheter thrombosis is 
0.3–28% [20].
Considering these factors, several risk models to predict the occurrence of 
cancer-associated VTE have been published. Khorana score is the most widely used 
risk model among them [21]. Five predictive variables are identified in this score: 
site of cancer (2 points for very high-risk site, 1 point for high-risk site), platelet 
Table 2. 
Risk factors for venous thromboembolism.
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count of 350 × 109/L or more, hemoglobin less than 100 g/L (10 g/dL) and/or the 
use of erythropoiesis-stimulating agents, leukocyte count more than 11 × 109/L, 
and body mass index of 35 kg/m2 or more (1 point each). Rates of VTE have been 
reported to be 0.3% in low-risk (score = 0), 2% in intermediate-risk (score = 1–2), 
and 6.7% in high-risk (score ≥ 3) category over a median of 2.5 months.
5. Pathogenesis of cancer-associated venous thromboembolism
Stasis of blood flow, hypercoagulability, and endothelial injury are known as 
Virchow’s triad, and they are involved in thrombus formation. Stasis of blood flow 
caused by several factors, such as poor performance status, indwelling CVC, and 
venous compression by tumor, is thought to be involved in the pathogenesis of VTE 
in cancer patients.
Blood cells also play an important role in the occurrence of VTE in cancer 
patients. Leukocyte count 11 × 109/L or above is a risk factor of VTE in cancer 
patients [21]. Increased leukocyte is found in 20–30% of cancer patients, and it is 
common in colon and lung cancer patients. Increased expression of granulocyte 
colony stimulating factor, granulocyte-macrophage colony stimulating factor, and 
interleukin-6 causes leukocyte increase in cancer patients [22, 23]. Neutrophils may 
enhance thrombosis through formation of neutrophil extracellular traps (NETs), 
which take in erythrocytes and platelets, and bind to tissue factor (TF) resulting in 
activation of coagulation [24, 25]. Increased incidences of VTE are reported both 
in cancer patients with thrombocytosis prior to cancer diagnosis and thrombocy-
tosis at cancer diagnosis [11, 26, 27]. Higher expression of platelet factor 4, which 
activates platelets, in cancer patients may be related to the development of VTE 
[28, 29]. Platelets also play a regulatory role in NETs formation. These may play an 
important role in the pathogenesis of cancer-associated VTE.
Some proteins also have been reported to be involved in the pathogenesis of can-
cer-associated VTE. TF plays an important role in hemostasis and activates factor 
IX and factor X to initiate extrinsic coagulation pathway by forming a complex with 
factor VII or activated factor VII. VTE most frequently occurs in pancreatic cancer 
patients, and pancreatic cancer expresses TF. Expression levels of TF correlate with 
histologic grades of cancer, and the incidence of VTE is higher in patients with 
pancreatic cancer with high TF expression level [30, 31]. Podoplanin is a protein 
which activates platelets by binding to platelet C-type lectin receptor 2 (CLEC-2) 
[32, 33]. The relationships between podoplanin and VTE are proven in patients with 
glioblastoma multiforme (GBM). Expression levels of podoplanin vary by GBM 
subtype. GBM with high podoplanin expression level has a high number of platelet 
aggregates in tumor vessels and is reported to have high  incidence of VTE [34].
P-selectin is a protein that exists in platelets and endothelial cells, and soluble 
form of P-selectin exists in plasma. P-selectin induces leukocytes to damaged 
endothelium for thrombus formation. The incidence of VTE is reported to be higher 
in cancer patients with high levels of soluble P-selectin [35]. Inhibition of P-selectin 
reduces thrombus formation in animal models [36].
Plasminogen activator inhibitor-1 (PAI-1) inhibits plasmin, which is synthesized 
from plasminogen to dissolve thrombus. Increased level of PAI-1 causes thrombotic 
tendency. The incidence of VTE is high in pancreatic cancer patients with increased 
levels of PAI-1 [37]. It is reported that administration of bevacizumab to mice trans-
planted with lung cancer cells increases PAI-1 expression and enlarges the size of 
thrombus. Administration of PAI-1 inhibitor to these mice decreases the thrombus 
size [38]. These findings suggest that increased PAI-1 may be related to the occur-
rence of cancer-associated VTE (Figure 1).
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6. Diet, nutrition, and VTE
Considering the pathogenesis of cancer-associated VTE described in the 
previous section, it is unlikely that certain diets and nutrition can suppress the 
development of cancer-associated VTE specifically. Then, are there any diets 
and nutrition which may prevent the development of VTE in general, not just 
cancer-associated? The association between diet and nutrition and thrombosis 
has not necessarily been well analyzed for VTE, but it has been well analyzed for 
arterial thrombosis such as ischemic heart disease or cerebral infarction. In 2010, 
the American College of Cardiology announced seven lifestyles to reduce deaths 
caused by cardiovascular and cerebral infarction by 20% by 2020: (1) nonsmoking, 
(2) body mass index <25 kg/m2, (3) physical activity at goal levels, (4) pursuit of 
a diet consistent with the current guideline recommendations, (5) untreated total 
cholesterol <200 mg/dL, (6) untreated blood pressure < 120/<80 mm Hg, and (7) 
fasting blood glucose <100 mg/dL [39]. Do these lifestyles also reduce the incidence 
of VTE? Hypertension, hypercholesterolemia, diabetes (these are related to diet and 
nutrition), and smoking are risk factors for atherosclerotic cardiovascular disease, 
and meta-analysis of nine clinical trials revealed that only smoking is a risk factor 
for VTE among them [40]. These results suggest that diets and nutrition to prevent 
arterial thrombosis are not necessarily effective for VTE prevention. On the other 
hand, obesity, one of the risk factors for arterial thrombosis, is also known to be one 
of the risk factors for the development of VTE. Analysis of the association between 
95 BMI-related gene polymorphisms and VTE development proves that five of the 
polymorphisms are associated with VTE development [41]. Therefore, taking a 
diet without too much calories or carbohydrates to maintain proper body weight is 
considered to be useful for VTE prevention.
Other reports examining the relationship between diet and nutrition and 
VTE are as follow. The incidence of VTE is 22% lower for those who eat fish 
three or more times a week than for those who eat twice or less a week [42] and 
is low for those who eat enough fish, vegetables, and fruits and eat less red meat 
and processed meat [43]. These reports suggest that diets to prevent arterial 
Figure 1. 
Pathogenesis of cancer-associated venous thromboembolism. Cancer cells express and release various proteins. 
These induce leukocytosis and thrombocytosis and activate coagulation resulting in thrombus formation.
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thrombosis might also be useful to prevent VTE. Furthermore, consumption 
of grape suppresses thrombin generation and enhances fibrinolysis [44]. Diets 
with 20, 30, and 50% of their calories on protein, lipids, and carbohydrates for 
12 months result in reduction of abdominal circumference, increased HDL-C, 
decreased fibrinogen, and significantly increased interleukin-10 in those with 
metabolic syndrome [45]. These reports suggest that diet and nutrition might 
directly affect the blood coagulation and fibrinolysis which play an important role 
in the  development of VTE.
Several reports related to the alcohol consumption and VTE have also been 
published. Women consuming alcohol daily were at 26% lower risk of VTE than 
non-consumers [46], and the analysis of three large US cohorts showed no evidence 
of an association of alcohol consumption amount or frequency with PE risk [47]. 
These findings suggest that alcohol drinking is not a risk factor for VTE.
7. Factors associated with carcinogenesis
The accumulation of various genetic abnormalities in normal cells causes 
carcinogenesis. Some cancers are caused by congenital genetic abnormalities, 
but most genetic abnormalities causing cancers are acquired abnormalities. It is 
estimated that smoking contributes to 20% of cancers and 23% of cancer deaths 
and infection with helicobacter pylori, hepatitis virus, etc. contributes to 21% of 
cancers and 22% of cancer deaths in Japanese population, and these are thought 
to be the main risk factors for cancer in Japanese population. Drinking alcohol 
contributes to 6% of both cancers and cancer deaths, and it is also a significant risk 
factor for cancer in Japanese population. Consumption of salt more than 6 g per 
day, deficiency of fruit intake, and deficiency of vegetable intake also contribute to 
1.6, 0.7, and 0.6% of cancers and 1.4, 0.8, and 0.6% of cancer deaths, respectively 
[48]. Diet and nutrition seem to have some effects on the development of cancer 
and cancer mortality.
8. Diet, nutrition, and cancer
According to a report “Food, Nutrition, Physical Activity, and the Prevention 
of Cancer: A Global Perspective” published by World Cancer Research Fund and 
American Institute for Cancer Research, it is convincing that adult body fatness 
has increased risks of esophageal, pancreatic, liver, colorectal, postmenopausal 
breast, endometrial, and kidney cancer. As for diets and nutrition, there exist causal 
relationships between aflatoxin and liver cancer, lean and processed meat and colon 
cancer, arsenic in drinking water and lung cancer, and high-dose beta-carotene 
supplements and lung cancer. On the other hand, whole grains and food containing 
dietary fiber decrease colorectal cancer. Non-starchy vegetables and fruits decrease 
aerodigestive cancer and some other cancers [49]. It is not fully understood how 
each diet and nutrition has effects on carcinogenesis, a diet with enough vegetables 
and fruits, less lean and processed meat, reduced carbohydrate and fat to prevent 
obesity, and low in salt might be useful to reduce cancer incidence.
9. Alcohol, cigarette smoking, and cancer
In 2017, the American Society of Clinical Oncology announced that alcohol 
drinking had been established as a risk factor for cancer, and avoiding excessive 
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drinking was important to prevent cancer [50]. The development of pharyngeal, 
laryngeal, esophageal, liver, breast, and colorectal cancer was obviously related to 
alcohol drinking. The incidence of esophageal cancer was 1.3 times higher for small 
drinkers, 2.2 times for moderate drinkers, and 5 times for heavy drinkers than non-
drinkers. Ethanol itself is not carcinogenic, but acetaldehyde, its metabolite, binds 
to DNA and proteins to be carcinogenic and mutagenic. It is proven that administra-
tion of large amount of ethanol or acetaldehyde causes cancer in animal experi-
ments [51]. Acetaldehyde is metabolized by aldehyde dehydrogenase 2 (ALDH2). 
Higher percentage of Japanese people has inactive form of ALDH2 compared to the 
Western. It might result in adverse effects of alcohol drinking on carcinogenesis in 
Japanese population.
Smoking is a well-known risk factor for cancer. The International Agency for 
Research on Cancer (IRAC) assessed causal relationships in 2009 and stated that 
smoking is related to oral, pharyngeal, laryngeal, esophageal, lung, gastric, colon, 
liver, pancreatic, renal cell, renal pelvis, ureter, bladder, cervical, and ovarian 
cancer and chronic myelogenous leukemia. Passive smoking is a risk factor for lung 
cancer [52]. To prevent cancer of yourself, your family, and your colleagues, no 
smoking is mandatory (Figure 2).
10. Aspirin and cancer
Aspirin is a widely used antiplatelet drug that inhibits platelets’ cyclooxygenase 
(COX), resulting in decreased platelet aggregation. Numerous studies have dem-
onstrated the effects of aspirin on the secondary prevention of arterial thrombosis, 
and several studies have investigated the effects of aspirin use for the primary 
prevention of atherosclerotic diseases. Meta-analyses of these studies have shown 
that daily regular aspirin use reduce the incidence of colon cancer, mortality of 
colon cancer, and metastasis of colon cancer. The incidence or mortality of other 
types of cancer might also be reduced [53–55]. Increased COX expression results 
in tumor growth and progression, and inhibition of COX reduces carcinogenesis 
in animal experiments. Platelets are known to play an important role in tumor 
metastasis [56]. These might be related to the inhibitory effects of aspirin on cancer 
reported in meta-analyses. On the other hand, some recent reports have shown that 
Figure 2. 
Effects of diets and lifestyle on cancer and venous thromboembolism (VTE). Fish, vegetables, and fruits may 
decrease the incidences of both cancer and VTE. Cigarette smoking and obesity increase the incidences of both 
cancer and VTE. Drinking alcohol and consuming lean and processed meat increase the incidence of cancer. 
Whole grain and dietary fiber decrease the incidence of cancer.
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regular aspirin use does not decrease cancer incidence or cancer mortality [57–59] 
(Table 3). Further studies are needed to confirm the effects of aspirin on cancer 
incidence and cancer mortality.
11. Conclusion
Various factors are involved in carcinogenesis and occurrence of cancer-associ-
ated VTE. Certain diets and nutrition may reduce the risk of VTE. Some lifestyles 
may reduce cancer incidence, and other lifestyles increase the risk of cancer. 
Further studies are needed to create ideal diet, nutrition, and lifestyle to reduce the 
risk of cancer and cancer-associated VTE.
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Outcome HR Reference
Incidnce of colon cancer 0.76(0.60 – 0.96) [53]
Death due to colon cancer 0.65(0.48 – 0.88) [53]
Death due to cancer 0.79(0.68 – 0.92) [54]
Cancer with disant metastasis 0.64(0.48 – 0.84) [55]
Outcome HR Reference
Incidence of cacer 1.24(1.06 –1.46) [57]
Death due to cancer 1.08(0.85 –1.38) [57]
Death due to cancer 1.31(1.10 –1.56) [58]
Incidence of cacer 1.01(0.92 –1.11) [59]
HR: Hazard ratio (aspirin vs placebo or no-aspirin).
Recent publications
Representative reports of large-scale meta-analysis
Table 3. 
Effects of aspirin on cancer incidence and cancer mortality.
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